Summary
This 8-K filing from Edwards Lifesciences (EW) on July 26, 2017, primarily serves to furnish a press release detailing the company's financial results for the second quarter of 2017. The report itself contains minimal new information beyond directing investors to the accompanying press release (Exhibit 99.1) for the operational and financial data. Therefore, the key insights for investors will be found within that press release, which covers the company's performance and financial condition during the specified quarter.
Key Highlights
- 1Disclosure of second quarter 2017 financial results via a press release.
- 2The press release is furnished as Exhibit 99.1 and incorporated by reference into the filing.
- 3This 8-K filing acts as a notification mechanism for the release of Q2 2017 financial performance.
- 4Investors should refer to Exhibit 99.1 for detailed financial figures and operational commentary.
- 5The filing is dated July 26, 2017, with the event date being July 25, 2017.
Frequently Asked Questions
The primary purpose of this 8-K filing is to officially release Edwards Lifesciences' financial results for the second quarter of 2017 through an accompanying press release.
The detailed financial results and commentary for the second quarter of 2017 are provided in the press release, which is furnished as Exhibit 99.1 to this 8-K filing and incorporated by reference.
No, the 8-K filing itself does not contain the specific financial data. It directs investors to the press release (Exhibit 99.1) for the company's second quarter 2017 financial results and condition.